Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells

Area of Science:

• Stem Cell Biology
• Genetic Engineering
• Drug Discovery

Background:

• Patient-specific induced pluripotent stem cells (iPSCs) hold promise for novel drug and cell therapies.
• Limited progress exists in iPSC-based drug screening for liver diseases, with low gene-targeting efficiency in human iPSCs.
• Alpha-1 antitrypsin (AAT) deficiency currently lacks effective drug or gene therapy options.

Purpose of the Study:

• To establish an iPSC-based platform for discovering drug candidates for AAT deficiency.
• To develop efficient gene-targeting methods for correcting the disease-causing mutation in AAT deficiency.
• To enable translation of iPSC technology into novel therapies for untreatable diseases.

Main Methods:

• Generated iPSC lines from patients with AAT deficiency.
• Implemented a high-throughput screening assay using hepatic differentiation protocol for automated quantification of AAT accumulation.
• Utilized a library of clinical compounds for drug screening.
• Employed transcription activator-like effector nuclease (TALEN) technology for gene targeting.

Main Results:

• Identified five clinical drugs that reduce AAT accumulation in iPSC-derived hepatocyte-like cells.
• Achieved high gene-targeting efficiency (25%-33%) in AAT-deficiency patient iPSCs using TALEN technology.
• Derived functional hepatocyte-like cells from gene-corrected iPSCs, free of mutant AAT accumulation.

Conclusions:

• Demonstrated the feasibility of effective large-scale drug screening using an iPSC-based disease model.
• Showcased highly robust gene targeting in human iPSCs.
• Highlighted the critical role of these advancements in translating iPSC technology into novel therapies for untreatable diseases.